Despite the fact that EGFR is frequently overexpressed in TNBC, tyrosine kinase inhibitors (TKIs), which are specific anti-EGFR agents, have only been used as part of the standard regimen for specific tumor types, such as gefitinib, erlotinib, afatinib, and osimertinib for non-small cell lung cancer (NSCLC), and erlotinib for pancreatic cancer [12]. Here, EGFR is linked to pancreatic neoplasm.